Immupharma will get 'real-world' data from the MAP with up to 500 patients to receive the drug free of charge for two years.
That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.
One big advantage is that' real-world' data can be used to supplement a regulatory filing.
Merck's Keytruda I/O cancer treatment made use MAP extensively for example.
An extension study to Lupozor's phase III study will also report next year, said McCarthy.